4 ms·

> Except that they wouldn't have any incentive to drop poorer countries vs. charging them the same price as everyone else. It's true, they wouldn't. However, t

> Except that they wouldn't have any incentive to drop poorer countries vs. charging them the same price as everyone else. It's true, they wouldn't. However, the buyers might not be able to afford it. If the average comes out to about 10-20k, then US/Westerners will be able to afford that, but poorer people will not, so they'll just completely skip the treatment. If you remove poor people from the market, that shifts the average up by a lot, and then the process repeats.

AnthonyMouse 13y ago
> If the average comes out to about 10-20k, then US/Westerners will be able to afford that, but poorer people will not, so they'll just completely skip the treatment. As opposed to your proposed alternative where the average US WalMart employee without health insurance is expected to pay $89K in cash up front? Or perhaps we'll just require them all to buy health insurance and the insurance company can cover the $89K by charging a $12K/year insurance premium to workers making the ~$15K/year federal minimum wage? The fundamental flaw you're making is US citizen = rich, which is factually incorrect. Especially if you expect them to subsidize medical care world-wide. > If you remove poor people from the market, that shifts the average up by a lot, and then the process repeats. Nonsense. The poorest people who would forgo life-saving drugs for financial reasons by definition have no money. Losing the minimal revenue they could have provided would have no effect on the drug company's revenues and require no recalculation. And once again, if you want to help those people in other countries, by all means propose a bill to explicitly subsidize medicine in those countries. But take the money to fund it from this country's rich rather than its poor.
- ahomescu1 13y ago
  > The fundamental flaw you're making is US citizen = rich, which is factually incorrect. Especially if you expect them to subsidize medical care world-wide. Price discrimination is only a subsidy if the drug manufacturers are selling the drug below cost in poor countries, therefore losing money on it. What's the marginal cost of the drug itself? I imagine it's pretty cheap, so the company makes a profit either way. Why would they sell in poor countries, if it loses them money? I see the cost of a drug as two parts: the one-time, large research cost, and the marginal cost per-treatment. The former is quite big (hundreds or thousands of millions of dollars), while the latter is quite small. This is why companies can afford such price discrimination. I can't really understand what kind of subsidy you're seeing here, except maybe for how poor countries get to benefit off research paid by rich country patients. Is that it? > Nonsense. The poorest people who would forgo life-saving drugs for financial reasons by definition have no money. I don't think that they really have "no money". The question is how much money they have. The Walmart worker in your example would probably be able to afford the treatment at India prices. The problem is that you can't easily do individual price discrimination in the same country. You can't sell the drug cheaply to the poor US worker, and very expensively to the American millionaire (if you could, that itself would be the solution to everyone's problems). > And once again, if you want to help those people in other countries, by all means propose a bill to explicitly subsidize medicine in those countries. But take the money to fund it from this country's rich rather than its poor. Drug companies don't take money from either rich or poor, they take it from whoever needs the drugs. Now if you're proposing government-funded or -operated drug research, that's another discussion. Otherwise, I don't see what the rich have to do with the economics of medical drugs. Also, after posting my previous comment, I realized I can make a good economic argument for price discrimination. When you look at countries as independent markets that a drug company operates in, the company will set the per-country price for each drug at the point where the profits for each country are maximized. In reality, the countries are not independent markets. The existence of black market for drugs in richer countries (where individuals smuggle in cheaper versions of a drug) should have a positive effect: it pulls the price down, due to the competition (because the company now has to compete with its own drug, it has to lower the price). The only real problem here is that, in many cases, it's either illegal or very difficult to move drugs across borders.

AnthonyMouse 13y ago

> If the average comes out to about 10-20k, then US/Westerners will be able to afford that, but poorer people will not, so they'll just completely skip the treatment. As opposed to your proposed alternative where the average US WalMart employee without health insurance is expected to pay $89K in cash up front? Or perhaps we'll just require them all to buy health insurance and the insurance company can cover the $89K by charging a $12K/year insurance premium to workers making the ~$15K/year federal minimum wage? The fundamental flaw you're making is US citizen = rich, which is factually incorrect. Especially if you expect them to subsidize medical care world-wide. > If you remove poor people from the market, that shifts the average up by a lot, and then the process repeats. Nonsense. The poorest people who would forgo life-saving drugs for financial reasons by definition have no money. Losing the minimal revenue they could have provided would have no effect on the drug company's revenues and require no recalculation. And once again, if you want to help those people in other countries, by all means propose a bill to explicitly subsidize medicine in those countries. But take the money to fund it from this country's rich rather than its poor.

ahomescu1 13y ago
> The fundamental flaw you're making is US citizen = rich, which is factually incorrect. Especially if you expect them to subsidize medical care world-wide. Price discrimination is only a subsidy if the drug manufacturers are selling the drug below cost in poor countries, therefore losing money on it. What's the marginal cost of the drug itself? I imagine it's pretty cheap, so the company makes a profit either way. Why would they sell in poor countries, if it loses them money? I see the cost of a drug as two parts: the one-time, large research cost, and the marginal cost per-treatment. The former is quite big (hundreds or thousands of millions of dollars), while the latter is quite small. This is why companies can afford such price discrimination. I can't really understand what kind of subsidy you're seeing here, except maybe for how poor countries get to benefit off research paid by rich country patients. Is that it? > Nonsense. The poorest people who would forgo life-saving drugs for financial reasons by definition have no money. I don't think that they really have "no money". The question is how much money they have. The Walmart worker in your example would probably be able to afford the treatment at India prices. The problem is that you can't easily do individual price discrimination in the same country. You can't sell the drug cheaply to the poor US worker, and very expensively to the American millionaire (if you could, that itself would be the solution to everyone's problems). > And once again, if you want to help those people in other countries, by all means propose a bill to explicitly subsidize medicine in those countries. But take the money to fund it from this country's rich rather than its poor. Drug companies don't take money from either rich or poor, they take it from whoever needs the drugs. Now if you're proposing government-funded or -operated drug research, that's another discussion. Otherwise, I don't see what the rich have to do with the economics of medical drugs. Also, after posting my previous comment, I realized I can make a good economic argument for price discrimination. When you look at countries as independent markets that a drug company operates in, the company will set the per-country price for each drug at the point where the profits for each country are maximized. In reality, the countries are not independent markets. The existence of black market for drugs in richer countries (where individuals smuggle in cheaper versions of a drug) should have a positive effect: it pulls the price down, due to the competition (because the company now has to compete with its own drug, it has to lower the price). The only real problem here is that, in many cases, it's either illegal or very difficult to move drugs across borders.